Aktieanalyser från populära analyshus

22 May 07:25

Flexion Mobile: Solid report with no surprises - Redeye

Flexion Mobile

22 May 07:25

North Media: A slow start, but the ball is rolling - ABG

Q1 miss mainly driven by FK and SDR Cutting '25e EBITDA/EBIT by 9/15%, small changes to '26e-'27e FV...

North Media

21 May 16:41

North Media: Q1 miss, reiterated guidance - ABG

Fiskars: Aiming to improve growth in Vita - Nordea

Fiskars hosted its "Get to know Vita" day today. The company has been building its "brand first" app...

Curasight: 47% subscription in the rights issue - Redeye

Flexion Mobile Q1 2025: In line with expectations - Redeye

Redeye comments on Flexion Mobile's Q1 2025 report, which was pretty much in line with expectations.

Lagercrantz: Twin engines working in tandem - Redeye

Oncopeptides Q1 2025: Strong Q/Q Growth with Japan the Next Catalyst - Redeye

Redey comments on Oncopeptides’ first quarter report 2025.

Alligator Bioscience: 71% Subscription Rate of TO12 - Redeye

Chargepanel: Successiv förbättring väntas under året - Mangold Insight Analys

För det första kvartalet 2025 var intäkterna 39 procent lägre än Mangolds prognos.

Cinclus Pharma Q1: Focus on upcoming pivotal study - Redeye

Scibase 1Q: Laying the groundwork for US expansion - Redeye

Redeye returns with a more in-depth take on the Q1 earnings.

Scibase

Analys | Analysguiden

20 May 12:19

Cell Impact: Svag marknad – behov av finansiering - Analysguiden

Kancera: Updates on Recardio collaboration - Redeye

Redeye provides a brief comment on Kancera’s update regarding the collaboration with Recardio and th...

Lagercrantz Q4 2024/2025: Stable report, matched our estimates - Redeye

Gullberg & Jansson: Rapportkommentar Q1'25 - Kalqyl

Underliggande tillväxt trots svagare kvartal Det första kvartalet var sammantaget svagare än motsva...

Gullberg & Jansson

19 May 15:20

Analyst Group kommenterar Aptahem och pågående företrädesemission

Dala Energi: Steady she goes - Redeye

Redeye reiterates its fair value range following Dala Energi’s Q1 report that was published last Fri...

Initiator Pharma: Indication expansion and SEK56.2m rights issue - Redeye

XP Chemistries: Positivt EFSA-utlåtande, en game changer - Mangold Insight Analys

I april 2025 lämnade EFSA (Europeiska myndigheten för livsmedelssäkerhet) ett positivt vetenskaplig...

Angler Gaming: Rapportkommentar Q1'25 - Kalqyl

Angler Gaming

19 May 10:59

Analyst Group kommenterar Biofrigas och pågående företrädesemission

Biofrigas Sweden AB (publ) (”Biofrigas” eller ”Bolaget”) är verksamma på den växande marknaden för f...

Biofrigas

19 May 10:57

Ogunsen: H2 recovery still on the cards - ABG

Ogunsen

19 May 10:56

Projektengagemang: Uncertainty remains - ABG

No real progress in Q1 Market to turn positive in '25e, according to report Turnaround delayed, '25e...

Projektengagemang

19 May 10:42

Energy Save: Cool Q2 ahead, but H2'25e set to heat up - ABG

Energy Save

19 May 10:05

STENOCARE: Time to Capitalize on STENOCARE 3.0 - Analyst Group

STENOCARE A/S (“STENOCARE” or the “Company”) is a medical cannabis trading company with products app...

Biovica: Signs its fourth tier-1 oncology Master Service Agreement based on DiviTum - Redeye

Angler Gaming kv1 2025: Starka marginaler men utebliven tillväxt - Carlsquare

Angler Gaming plc (”Angler” eller ”Bolaget”) levererade en kv1 2025-rapport under vår förväntan avse...

Angler Gaming